Galera Therapeutics (NASDAQ:GRTX) Downgraded by HC Wainwright to Neutral

Galera Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Galera Therapeutics Downgraded by HC Wainwright on 10/20/2021. In a note to investors, the firm issued a new rating of Neutral. The analysts previously had rating of Buy.

View More Galera Therapeutics (NASDAQ:GRTX) Downgraded by HC Wainwright to Neutral

Flexion Therapeutics (NASDAQ:FLXN) Downgraded by HC Wainwright to Neutral

Flexion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by HC Wainwright on 10/19/2021. In a note to investors, the firm issued a new rating of Neutral. The analysts previously had rating of Buy.

View More Flexion Therapeutics (NASDAQ:FLXN) Downgraded by HC Wainwright to Neutral

Medical sector’s BioDelivery Sciences International’s (NASDAQ:BDSI) Buy rating Reiterated by HC Wainwright

BioDelivery Sciences International (NASDAQ:BDSI)‘s stock had its Buy rating Reiterated by by analysts at N/A in a research report issued to clients and investors.

View More Medical sector’s BioDelivery Sciences International’s (NASDAQ:BDSI) Buy rating Reiterated by HC Wainwright

Adamas Pharmaceuticals (NASDAQ:ADMS) Downgraded by HC Wainwright to Neutral

Adamas Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Adamas Pharmaceuticals Downgraded by HC Wainwright on 10-12-21. In a note to investors, the firm issued a new rating of Neutral. The analysts previously had rating of Buy.

View More Adamas Pharmaceuticals (NASDAQ:ADMS) Downgraded by HC Wainwright to Neutral